Translate 
Abstract
Abstract Laryngeal and hypopharyngeal cancers are among the top 20 cancers in India. Most of these patients present with stage III/IV cancer. Many among these patients may be suitable for the organ preservation protocol. There is sparse data from India on the regimen used for organ preservation strategies, and the salvage of the larynx for any failures after this. In this study, we attempted to identify the regimens used for organ preservation for laryngeal and hypopharyngeal cancer, the larynx preservation rates and the salvage laryngectomy rates for local/locoregional failures. We initially performed a literature search to identify what is available, followed by a survey to understand the present practice patterns and the results. The published literature showed that weekly cisplatin is being utilised for organ preservation strategies commonly, in contrast to the once in 3-week 100 mg/m2 that were used in the landmark trials. The salvage laryngectomy rates reported in the literature ranged between 1.8 and 54%. Also, the survey had similar findings. The regimen used for organ preservation was not the one used in the landmark trials. The literature is limited concerning the reporting of the salvage laryngectomy rates following organ preservation strategies.
Highlights
Randomised controlled trials on larynx preservation in locally advanced laryngeal and hypopharyngeal cancer in the 1990 s and early 2000 s have brought about a paradigm shift in their management from total laryngectomy to concurrent chemoradiotherapy as the standard of care
We included articles published from institutes or centres from India between 2000 to 2025, which reported on adult patients who received definitive treatment for organ preservation for locally advanced laryngeal and hypopharyngeal carcinoma and reported on the salvage laryngectomy rates from India
This study opens up the issue of limited reporting of the treatment regimens used for organ preservation, organ preservation rate and the incidence or need for salvage total laryngectomy following organ preservation protocol
Summary
Randomised controlled trials on larynx (organ) preservation in locally advanced laryngeal and hypopharyngeal cancer in the 1990 s and early 2000 s have brought about a paradigm shift in their management from total laryngectomy to concurrent chemoradiotherapy as the standard of care. The RTOG 91–11 trial established concurrent chemoradiotherapy as the standard of care for locally advanced laryngeal cancer, with a larynx preservation rate of 88% at 2 years without. In India, laryngeal and hypopharyngeal cancers are the 13 th and 15 th most common cancers, and they usually present with stage III or IV disease [7, 8]. Many of these patients present with bulky/large nodal burden, which was not adequately represented in the landmark trials.
Sign-in/Register to view highlights & summary 
Paper version not known (
Free)
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
